JM 118

Known as: JM-118, JM118 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1995-2013
02419952013

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
INTRODUCTION Chemotherapy for advanced well-differentiated carcinoids is characterised by low response rates and short duration… (More)
Is this relevant?
2010
2010
PURPOSE Dichloroacetate (DCA) inhibits pyruvate dehydrogenase kinase (PDK), and thus promotes glucose oxidation over glycolysis… (More)
  • figure 1
  • figure 2
  • table 1
Is this relevant?
2005
2005
Satraplatin is an orally bioavailable platinum analog that has activity in prostate cancer. JM118 is the most abundant species… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2005
2005
The hydrolysis process of the anticancer drug cis-amminedichlorocyclohexylamineplatinum(II) (JM118 or cis-[PtCl2(NH3… (More)
Is this relevant?
2005
2005
Background. Satraplatin is thought to require reduction to a reactive Pt(II) complex (JM118) before exerting chemotherapeutic… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2002
2002
The aim of this study is to establish anti-tumour potency of the new oral platinum drug JM216 and its metabolite JM118 in… (More)
Is this relevant?
1996
1996
 This study evaluates the metabolic profile of JM216 [bis(acetato)ammine-dichloro(cyclohexylamine) platinum(IV)], the first… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
1996
1996
This study evaluates the metabolism of the oral platinum drug JM216 [bis(acetato) amminedichloro (cyclohexylamine)platinum (IV… (More)
Is this relevant?
1995
1995
The mechanisms by which cis-diamminedichloroplatinum(II) (cisplatin) is transported across the plasma membrane (i.e., passive… (More)
Is this relevant?
1995
1995
We have investigated the comparative initial DNA binding properties of 7 platinum-based anticancer drugs: 5 cis-oriented… (More)
Is this relevant?